Molecule
Triheptanoin is a medium-chain triglyceride indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD). It is available as oral liquid. MedsAcross supplies Triheptanoin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
DOJOLVI is indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD). DOJOLVI is a medium-chain triglyceride indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).
Source: US FDA prescribing information
Triheptanoin is a medium-chain triglyceride consisting of three odd-chain 7-carbon length fatty acids (heptanoate) that provide a source of calories and fatty acids to bypass the long-chain FAOD enzyme deficiencies for energy production and replacement.
Source: US FDA prescribing information
Assess metabolic requirements by determining daily caloric intake (DCI) prior to calculating the dose of DOJOLVI. For patients receiving another medium-chain triglyceride product, discontinue prior to the first dose of DOJOLVI. The recommended target daily dosage of DOJOLVI is up to 35% of the patient's total prescribed DCI divided into at least four doses and mixed thoroughly into semi-solid food/liquid or medical food/formula at mealtimes or with snacks. See the full prescribing information for instructions on how to calculate the volume per dose, initiate and titrate the dosage to achieve the target, and prepare and administer DOJOLVI.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
Feeding Tube Dysfunction: Regularly monitor the feeding tube to ensure proper functioning and integrity. Intestinal Malabsorption in Patients with Pancreatic Insufficiency: Low or absent pancreatic enzymes may reduce absorption of DOJOLVI. Avoid administration of DOJOLVI in patients with pancreatic insufficiency.
Source: US FDA prescribing information
Most common adverse reactions are (≥10%): abdominal pain, diarrhea, vomiting, and nausea.
Source: US FDA prescribing information
Pancreatic Lipase Inhibitors: Avoid co-administration due to potential for reduced clinical effect of DOJOLVI. Pancreatic Lipase Inhibitors Co-administration of triheptanoin with a pancreatic lipase inhibitor (e.g., orlistat) may reduce exposure to the triheptanoin metabolite, heptanoate, and reduce the clinical effect of triheptanoin. Avoid co-administration of DOJOLVI with pancreatic lipase inhibitors.
Source: US FDA prescribing information
Store at 20° to 25°C (68° to 77°F), excursions permitted to 15° to 30°C (59° to 86°F). Do not freeze. Do not dose or store using materials made of polystyrene or polyvinyl chloride (PVC) containers.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Triheptanoin, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Dojolvi 0.96 g/mL oral liquidOral | Ultragenyx Pharmaceutical | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 30 June 2020 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 1 presentations of Triheptanoin and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Triheptanoin, including Dojolvi.
Yes. The US FDA first approved Triheptanoin on 30 June 2020, according to Drugs@FDA.
No listed presentation of Triheptanoin is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.